Cross-reactive neutralizing antibody epitopes against Enterovirus 71 identified by an in silico approach

Vaccine

Volumn 30, Issue 49, 2012, Pages 7105-7110

  Kirk, K ^a   Poh, C L ^b   Fecondo, J ^a   Pourianfar, H ^c   Shaw, J ^a   Grollo, L ^a  

^a SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^b SUNWAY UNIVERSITY   (Malaysia)

^c Iranian Academic Centre for Education Culture and Research (ACECR)   (Iran)

Author keywords

Antibodies; Enterovirus 71; In silico analysis; Synthetic peptides

Indexed keywords

CAPSID PROTEIN; CROSS REACTING ANTIBODY; EPITOPE; NEUTRALIZING ANTIBODY; PEPTIDE VACCINE; PROTEIN VP1; PROTEIN VP2; PROTEIN VP3; PROTEIN VP4; SYNTHETIC PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; BAGG ALBINO MOUSE; COMPUTER MODEL; CONTROLLED STUDY; ENCEPHALITIS; ENDEMIC DISEASE; ENTEROVIRUS 71; FLACCID PARALYSIS; HAND FOOT AND MOUTH DISEASE; HERPANGINA; HIDDEN MARKOV MODEL; IN VITRO STUDY; INOCULATION; INSULIN DEPENDENT DIABETES MELLITUS; LEARNING; MALE; MENINGOENCEPHALITIS; MOUSE; NONHUMAN; PACIFIC ISLANDS; PERICARDITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PROPENSITY SCORE; VIRUS MENINGITIS; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; COMPUTATIONAL BIOLOGY; CROSS REACTIONS; ENTEROVIRUS A, HUMAN; EPITOPES, B-LYMPHOCYTE; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; VACCINES, SUBUNIT;

EID: 84869089930     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.030     Document Type: Article

References (42)

1. Stanway G., Kinnunen L., Hyypiä T., Brown B., Horsnell C., Hovi T., et al. Genetic and phylogenetic clustering of enteroviruses. J Gen Virol 1996, 77(August (8)):1699-1717.
2. Christen U. Enterovirus infection of human beta-cells activates dendritic cells and triggers innate antiviral responses: are enteroviruses convicted now?. Diabetes 2010, 59(May (5)):1126-1128.
3. Oikarinen M., Tauriainen S., Oikarinen S., Honkanen T., Collin P., Rantala I., et al. Type 1 diabetes is associated with enterovirus infection in gut mucosa. Diabetes 2012, 61(March (3)):687-691.
4. Purcell A.W., McCluskey J., Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007, 6(5):404-414.
5. Beignon A.S., Brown F., Eftekhari P., Kramer E., Briand J.P., Muller S., et al. A peptide vaccine administered transcutaneously together with cholera toxin elicits potent neutralising anti-FMDV antibody responses. Vet Immunol Immunopathol 2005, 104(April (3-4)):273-280.
6. Deliyannis G., Jackson D.C., Ede N.J., Zeng W., Hourdakis I., Sakabetis E., et al. Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. J Virol 2002, 76(May (9)):4212-4221.
7. Dong X.N., Chen Y.H. Candidate peptide-vaccines induced immunity against CSFV and identified sequential neutralizing determinants in antigenic domain A of glycoprotein E2. Vaccine 2006, 24(March (11)):1906-1913.
8. Embers M.E., Budgeon L.R., Pickel M., Christensen N.D. Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol 2002, 76(October (19)):9798-9805.
9. Jackson D.C., Lau Y.F., Le T., Suhrbier A., Deliyannis G., Cheers C., et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci USA 2004, 101(October (43)):15440-15445.
10. Hofmann H.J., Hadge D. On the theoretical prediction of protein antigenic determinants from amino acid sequences. Biomed Biochim Acta 1987, 46(11):855-866.
11. Hopp T.P., Woods K.R. Prediction of protein antigenic determinants from amino acid sequences. Proc Natl Acad Sci USA 1981, 78(June (6)):3824-3828.
12. Parker J.M., Guo D., Hodges R.S. New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites. Biochemistry 1986, 25(September (19)):5425-5432.
13. Pellequer J.L., Westhof E., Van Regenmortel M.H. Predicting location of continuous epitopes in proteins from their primary structures. Methods Enzymol 1991, 203:176-201.
14. Blythe M.J., Benchmarking Flower D.R. B cell epitope prediction: underperformance of existing methods. Protein Sci 2005, 14(January (1)):246-248.
15. Larsen J.E., Lund O., Nielsen M. Improved method for predicting linear B-cell epitopes. Immunome Res 2006, 2:2.
16. Saha S., Raghava G.P.S. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins 2006, 65(1):40-48.
17. Rubinstein N.D., Mayrose I., Martz E., Pupko T. Epitopia: a web-server for predicting B-cell epitopes. BMC Bioinformatics 2009, 10:287.
18. Emini E.A., Hughes J.V., Perlow D.S., Boger J. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol 1985, 55(September (3)):836-839.
19. Kyte J., Doolittle R.F. A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982, 157(1):105-132.
20. Altschul S.F., Madden T.L., Schaffer A.A., Zhang J., Zhang Z., Miller W., et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997, 25(September (17)):3389-3402.
21. Chenna R., Sugawara H., Koike T., Lopez R., Gibson T.J., Higgins D.G., et al. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 2003, 31(July (13)):3497-3500.
22. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., et al. UCSF Chimera - a visualization system for exploratory research and analysis. J Comput Chem 2004, 25(October (13)):1605-1612.
23. Eswar N., Webb B., Marti-Renom M.A., Madhusudhan M.S., Eramian D., Shen M.Y., et al. Comparative protein structure modeling using MODELLER. Current Protocols in Protein Science 2007, Chapter 2, Unit 2.9.
24. Foo D.G.W., Alonso S., Phoon M.C., Ramachandran N.P., Chow V.T.K., Poh C.L. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res 2007, 125(1):61-68.
25. Chan P.W. Fmoc solid phase peptide synthesis: a practical approach 2000, Oxford University Press.
26. Leclerc C., Deriaud E., Mimic V., van der Werf S. Identification of a T-cell epitope adjacent to neutralization antigenic site 1 of poliovirus type 1. J Virol 1991, 65(February (2)):711-718.
27. Reed L.J., Muench H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol 1938, 27(May (3)):493-497.
28. Voller A., Bartlett A., Bidwell D.E., Clark M.F., Adams A.N. The detection of viruses by enzyme-linked immunosorbent assay (ELISA). J Gen Virol 1976, 33(October (1)):165-167.
29. Zeng W., Ghosh S., Lau Y.F., Brown L.E., Jackson D.C. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol 2002, 169(November (9)):4905-4912.
30. Frey A., Di Canzio J., Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 1998, 221(1-2):35-41.
31. Vorndam V., Beltran M. Enzyme-linked immunosorbent assay-format microneutralization test for dengue viruses. Am J Trop Med Hyg 2002, 66(February (2)):208-212.
32. Liu C.C., Chou A.H., Lien S.P., Lin H.Y., Liu S.J., Chang J.Y., et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine 2011, 29(June (26)):4362-4372.
33. Etlinger H., Gillessen D., Lahm H., Matile H., Schonfeld H., Trzeciak A. Use of prior vaccinations for the development of new vaccines. Science 1990, 249(July (4967)):423-425.
34. Schutze M.P., Leclerc C., Jolivet M., Audibert F., Chedid L. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol 1985, 135(October (4)):2319-2322.
35. Partidos C.D., Obeid O.E., Steward M.W. Antibody responses to non-immunogenic synthetic peptides induced by co-immunization with immunogenic peptides. Immunology 1992, 77(October (2)):262-266.
36. Härkönen T., Paananen A., Lankinen H., Hovi T., Vaarala O., Roivainen M. Enterovirus infection may induce humoral immune response reacting with islet cell autoantigens in humans. J Med Virol 2003, 69(3):426-440.
37. Oberste M.S., Maher K., Kilpatrick D.R., Pallansch M.A. Molecular evolution of the human enteroviruses: correlation of serotype with VP1 sequence and application to Picornavirus classification. J Virol 1999, 73(March (3)):1941-1948.
38. Chen H-F., Chang M-H., Chiang B-L., Jeng S-T. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from Enterovirus 71. Vaccine 2006, 24(15):2944-2951.
39. Wu C.-N., Lin Y.-C., Fann C., Liao N.-S., Shih S.-R., Ho M.-S. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2001, 20(5-6):895-904.
40. Khetsuriani N., LaMonte A., Oberste M.S., Pallansch M. Neonatal enterovirus infections reported to the National Enterovirus Surveillance System in the United States, 1983-2003. Pediatr Infect Dis J 2006, 25(10):889-893. 10.1097/01.inf.0000237798.07462.32.
41. Miao L.Y., Pierce C., Gray-Johnson J., DeLotell J., Shaw C., Chapman N., et al. Monoclonal antibodies to VP1 recognize a broad range of enteroviruses. J Clin Microbiol 2009, 47(10):3108-3113.
42. Liu C.-C., Chou A.-H., Lien S.-P., Lin H.-Y., Liu S.-J., Chang J.-Y., et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine 2011, 29(26):4362-4372.